Given that, many researchers have dedicated to exploring novel biomarkers such as isocitrate dehydrogenase (IDH) mutation, 1p19q codeletion, and O-6-methylguanine DNA methyltransferase (MGMT) promoter methylation in glioma for a better classification of glioma patients, which is more likely to fulfill precision medicine of glioma and prolong the survival of glioma patients. The gene discussed is MGMT; the disease is central nervous system cancer.